Edwards Lifesciences (EW) PT Raised to $155 at Canaccord Genuity on 2Q Beat; 'Keep Buying... Upside to Raised Guidance in the Cards'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Edwards Lifesciences (EW) PT Raised to $130 at Stifel; Reiterates Buy
July 27, 2017 8:30 AM EDTStifel raised its price target on Edwards Lifesciences (NYSE: EW) to $130.00 (from $118.00) while maintaining a Buy rating. For 3Q17, the company anticipates revenue between $810M-$850M with EPS at $0.80-$0.90 (mid-point: $0.85).
For 2017, Edwards now expects full-year revenue at the higher end of the $3.2 billion... More
Edwards Lifesciences (EW) PT Raised to $132 at Jefferies
July 27, 2017 7:33 AM EDTJefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $132.00 (from $115.00) while maintaining a Buy rating following the company's 2Q. EW put up another impressive TAVR Q with +23.3% underlying y/y growth and +7% growth sequentially. After adding back $22.5mn of German inventory... More
Edwards Lifesciences (EW): TAVR Outperformance Drives A PT Increase - Cowen
July 27, 2017 6:49 AM EDTCowen analyst, Joshua Jennings, reiterated his Outperform rating on shares of Edwards Lifesciences (NYSE: EW) and raised his price target to $135 after S3s strong sequential U.S. growth, international TAVR outperformance, outsized margin results and a ~$0.07 EPS beat (adjusting for the... More
Edwards Lifesciences (EW) Tops Q2 EPS by 20c; Raises Outlook
July 26, 2017 4:19 PM EDTEdwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.08, $0.20 better than the analyst estimate of $0.88. Revenue for the quarter came in at $842 million versus the consensus estimate of $840.06 million.
GUIDANCE:
Edwards Lifesciences sees FY2017 EPS of $3.65-$3.85, versus the consensus of... More
